General Information of This Antigen (ID: TAR0DDBTM)
Antigen Name
T-lymphocyte activation antigen CD86 (CD86)
Gene Name
CD86
Gene ID
942
Synonym
CD28LG2; Activation B7-2 antigen;B70;BU63;CTLA-4 counter-receptor B7.2;FUN-1;CD86
Sequence
MDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQ
ENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGM
IRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTI
EYDGVMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQ
PPPDHIPWITAVLPTVIICVMVFCLILWKWKKKKRPRNSYKCGTNTMEREESEQTKKREK
IHIPERSDEAQRVFKSSKTSSCDKSDTCF

    Click to Show/Hide
Function
Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Also involved in the regulation of B cells function, plays a role in regulating the level of IgG(1) produced. Upon CD40 engagement, activates NF-kappa-B signaling pathway via phospholipase C and protein kinase C activation.

    Click to Show/Hide
Uniprot Entry
CD86_HUMAN
HGNC ID
HGNC:1705
KEGG ID
hsa:942
Each Antibody-drug Conjugate and Its Component Related to This Antigen
Full List of The ADC Related to This Antigen
The Numbers of ADCs, Their Three Components, Payload Targets, and Corresponding Diseases for This Antigens
Anti-CD86 mAb 1G10
ADC Name Payload Target Linker ADC Info
Anti-B7-2-gelonin immunotoxin [1]
Gelonin
Ribosome (RB)
Undisclosed
Ipilimumab
ADC Name Payload Target Linker ADC Info
CN117281900A Ipi-L+CP1 [2]
CN117281900A Ipi-L+CP5 payload
Undisclosed
Ethylmaleimide linker
CN117281900A Ipi-L+CP2 [2]
CN117281900A Ipi-L+CP6 payload
Undisclosed
Ethylmaleimide linker
CN117281900A Ipi-L+CP3 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP4 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP5 [2]
CN117281900A Ipi-L+CP5 payload
Undisclosed
CN117281900A Ipi-L+CP22 linker
CN117281900A Ipi-L+CP6 [2]
CN117281900A Ipi-L+CP6 payload
Undisclosed
CN117281900A Ipi-L+CP22 linker
CN117281900A Ipi-L+CP7 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP8 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP9 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP10 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP11 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP12 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP13 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP14 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP15 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP16 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP17 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP18 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP19 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP20 [2]
CN117281900A Ipi-L+CP20 payload
Undisclosed
CN117281900A Ipi-L+CP22 linker
CN117281900A Ipi-L+CP21 [2]
CN117281900A Ipi-L+CP21 payload
Undisclosed
CN117281900A Ipi-L+CP22 linker
CN117281900A Ipi-L+CP22 [2]
CN117281900A Ipi-L+CP22 payload
Undisclosed
CN117281900A Ipi-L+CP22 linker
CN117281900A Ipi-L+CP23 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP24 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP25 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP26 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP27 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP28 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP29 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP30 [2]
Undisclosed
Undisclosed
Undisclosed
CN117281900A Ipi-L+CP31 [2]
Undisclosed
Undisclosed
Undisclosed
References
Ref 1 In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J Haematol. 2000 Aug;110(2):351-61. doi: 10.1046/j.1365-2141.2000.02193.x.
Ref 2 Tumor microenvironment-activated anti-CTLA-4 antibody conjugates and their applications